See more : Samyang Foods Co., Ltd. (003230.KS) Income Statement Analysis – Financial Results
Complete financial analysis of ShockWave Medical, Inc. (SWAV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ShockWave Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Bounce Mobile Systems, Inc. (BNCM) Income Statement Analysis – Financial Results
- Rorze Corporation (6323.T) Income Statement Analysis – Financial Results
- Medcomtech, S.A. (MED.MC) Income Statement Analysis – Financial Results
- FireFly Metals Ltd (MNXMF) Income Statement Analysis – Financial Results
- AB SKF (publ) (SKFRY) Income Statement Analysis – Financial Results
ShockWave Medical, Inc. (SWAV)
About ShockWave Medical, Inc.
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 730.23M | 489.73M | 237.15M | 67.79M | 42.93M | 12.26M | 1.72M |
| Cost of Revenue | 95.39M | 65.00M | 41.44M | 20.99M | 17.16M | 7.25M | 2.84M |
| Gross Profit | 634.84M | 424.74M | 195.71M | 46.80M | 25.77M | 5.01M | -1.12M |
| Gross Profit Ratio | 86.94% | 86.73% | 82.53% | 69.03% | 60.03% | 40.88% | -64.98% |
| Research & Development | 145.65M | 81.68M | 50.54M | 36.93M | 32.85M | 22.70M | 17.96M |
| General & Administrative | 95.27M | 56.93M | 34.75M | 23.86M | 14.13M | 5.98M | 5.42M |
| Selling & Marketing | 234.84M | 162.00M | 111.29M | 51.67M | 30.62M | 17.54M | 6.36M |
| SG&A | 323.20M | 218.92M | 146.04M | 75.54M | 44.75M | 23.52M | 11.79M |
| Other Expenses | 23.96M | 1.06M | -582.00K | 1.26M | 2.35M | 589.00K | 366.00K |
| Operating Expenses | 468.85M | 300.60M | 196.58M | 112.46M | 77.61M | 46.21M | 29.75M |
| Cost & Expenses | 564.24M | 365.60M | 238.02M | 133.45M | 94.77M | 53.46M | 32.58M |
| Interest Income | 0.00 | 1.89M | 1.10M | 1.21M | 944.00K | 0.00 | 0.00 |
| Interest Expense | 6.20M | 1.89M | 1.10M | 1.21M | 944.00K | 401.00K | 58.00K |
| Depreciation & Amortization | 10.36M | -1.42M | -6.87M | 1.26M | 2.35M | 700.00K | 468.00K |
| EBITDA | 176.35M | 127.57M | -871.00K | -62.32M | -49.56M | -39.91M | -30.03M |
| EBITDA Ratio | 24.15% | 25.06% | -3.26% | -95.01% | -115.30% | -325.46% | -1,747.00% |
| Operating Income | 165.99M | 124.13M | -871.00K | -65.66M | -51.84M | -41.20M | -30.87M |
| Operating Income Ratio | 22.73% | 25.35% | -0.37% | -96.86% | -120.76% | -335.97% | -1,795.52% |
| Total Other Income/Expenses | 8.29M | -3.31M | -7.96M | 44.00K | 792.00K | 136.00K | 276.00K |
| Income Before Tax | 174.28M | 120.83M | -8.84M | -65.62M | -51.05M | -41.06M | -30.59M |
| Income Before Tax Ratio | 23.87% | 24.67% | -3.73% | -96.80% | -118.92% | -334.86% | -1,779.46% |
| Income Tax Expense | 27.00M | -95.17M | 301.00K | 80.00K | 62.00K | 38.00K | 26.00K |
| Net Income | 147.28M | 216.00M | -9.14M | -65.70M | -51.11M | -41.10M | -30.62M |
| Net Income Ratio | 20.17% | 44.10% | -3.85% | -96.92% | -119.06% | -335.17% | -1,780.98% |
| EPS | 4.01 | 6.02 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
| EPS Diluted | 3.85 | 5.70 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
| Weighted Avg Shares Out | 36.71M | 35.90M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
| Weighted Avg Shares Out (Dil) | 38.21M | 37.88M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
SWAV Stock Alert: Shockwave Medical Lands Big Buyer in Johnson & Johnson
Johnson & Johnson (NYSE: JNJ ) is buying medical device company Shockwave Medical (NASDAQ: SWAV ) for $13.1 billion. Shockwave makes devices that perform Intravascular Lithotripsy.
Johnson & Johnson To Buy Shockwave Medical For $13.1 Billion
Johnson & Johnson will pay $13.1 billion, or $335 a share, for Shockwave Medical, which has soared in 2024 in part on takeover speculation.
SWAV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Shockwave Medical, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Shockwave Medical, Inc. (NASDAQ: SWAV) to Johnson & Johnson for $335.00 per share in cash is fair to Shockwave shareholders. Halper Sadeh encourages Shockwave...
Johnson & Johnson to buy Shockwave Medical for $12.5 billion
Shockwave Medical Inc (NASDAQ: SWAV) is in the green today after Johnson & Johnson (NYSE: JNJ) said it will buy the medical device maker for $12.5 billion. Shockwave Medical stock priced at a premium The all-cash agreement values each share...
Johnson & Johnson to buy Shockwave Medical for $12.5 billion
Shockwave Medical Inc (NASDAQ: SWAV) is in the green today after Johnson & Johnson (NYSE: JNJ) said it will buy the medical device maker for $12.5 billion. Shockwave Medical stock priced at a premium The all-cash agreement values each share...
Johnson & Johnson to Buy Shockwave Medical. It's a Cardio Health Play.
Johnson & Johnson is buying the medical-devices maker for a total enterprise value of about $13.1 billion.
Johnson & Johnson to acquire Shockwave Medical in $13.1 billion deal
Johnson & Johnson JNJ, -1.14% has agreed to acquire Shockwave Medical Inc. SWAV, -0.23% in an all-cash deal with an enterprise value of about $13 billion, the companies said Friday. J&J will pay $335 a share in cash, equal to...
Johnson & Johnson to buy Shockwave Medical for $12.5 bln
Johnson & Johnson will buy medical device maker Shockwave Medical for about $12.5 billion, the companies said on Friday, helping the healthcare conglomerate boost its portfolio of medical devices.
Johnson & Johnson to Acquire Shockwave Medical
NEW BRUNSWICK, N.J. & SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of...
Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Source: https://incomestatements.info
Category: Stock Reports